Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Osteoporosis symbols : AMGN save search
Global Postmenopausal Osteoporosis Treatment Market 2023-2030: Asia-Pacific Showing Strong Growth Potential
Published: 2023-08-22 (Crawled : 22:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.56%
H: 0.1%
C: -0.32%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.55%
H: 0.12%
C: -0.6%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.73%
H: 0.13%
C: -0.82%
osteoporosis treatment global potential growth market
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Published: 2023-02-15 (Crawled : 15:20) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 2.34%
H: 9.2%
C: 8.45%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -0.06%
eb613 treatment meeting review osteoporosis
Global Osteoporosis Drugs Market Report 2022: Anabolic Drug Developments Show High Potential to Reshape Sector
Published: 2022-11-07 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.13%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -3.09%
H: 0.72%
C: -0.09%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.17%
H: 2.51%
C: 1.97%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.33%
H: 3.48%
C: 3.31%
drug global report potential market osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.0%
H: 7.73%
C: 6.61%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.62%
H: 0.65%
C: -2.04%
eb613 treatment impact potential osteoporosis
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
Global Osteoporosis Treatment Market to Surpass US$ 18.92 Billion by 2030 - Coherent Market Insights
Published: 2022-07-12 (Crawled : 18:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.4%
H: 3.2%
C: 2.1%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.13%
H: 0.14%
C: -0.52%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.32%
H: 0.6%
C: -1.94%
NNOX | $8.62 -4.96% -5.22% 1M
|
Health Technology
|
| O: -0.5%
H: 5.47%
C: 3.62%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -0.3%
H: 3.16%
C: 2.67%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.93%
C: -0.33%
treatment market osteoporosis
Osteoporosis Drugs Market - 38% of Growth to Originate from North America |Antiresorptive Drugs Segment to be Significant for Revenue Generation | 17000+ Technavio Reports
Published: 2022-01-18 (Crawled : 17:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: 0.0%
america drug report growth osteoporosis
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
Published: 2021-08-02 (Crawled : 13:15) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 5.4%
H: 2.66%
C: 1.71%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.37%
H: 0.15%
C: -0.96%
treatment phase 2 bone eb613 research osteoporosis
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.